RxDoctor Payments Data

Carol Espinal, MD

Family Medicine · Orlando, FLNPI 1548421894

Payments from drug & device makers

$1,332in general payments, 2019–2025

Across 68 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$334
  • AstraZeneca$217
  • Novo Nordisk$171
  • Lilly USA, LLC$150
  • Bayer$111
  • Exact Sciences$79
  • plus $269 from 8 others

What the payments were for

  • Food & beverage$1,332100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,332 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$30,859
Medicare patients
72
Services billed
713

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate104$149,712
JardianceEmpagliflozin97$132,569
OzempicSemaglutide71$105,035
FarxigaDapagliflozin Propanediol76$104,346
IngrezzaValbenazine Tosylate11$75,017
EliquisApixaban63$62,969
TrulicityDulaglutide21$35,740
RybelsusSemaglutide15$31,560
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$31,558
LinzessLinaclotide16$22,998
MyrbetriqMirabegron25$21,516
MounjaroTirzepatide17$18,675
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$10,492
Tresiba Flextouch U-100Insulin Degludec13$9,089
SymbicortBudesonide/Formoterol Fumarate19$4,872

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$171$136,59586 claims
Boehringer IngelheimJardiance$52$132,56997 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$217$119,710112 claims
PfizerEliquis$34$62,96963 claims
Lilly USA, LLCTrulicity, Mounjaro$150$54,41538 claims
GSKTrelegy Ellipta$334$31,55837 claims
Sanofi-aventis U.S. LLCLantus$12$1,84611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →